Relapsed refractory multiple myeloma with CNS involvement successfully treated with Elranatamab: first reported case

Central nervous system (CNS) involvement in multiple myeloma (MM) is a rare and challenging complication associated with poor prognosis and limited treatment options. Emerging T-cell directing therapies, such as bispecific antibodies (bsAbs) and chimeric antigen receptor T cells (CAR-T), have shown...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in immunology Vol. 14
Main Authors Mutlu, Yasa Gul, Yıgıt Kaya, Sureyya, Maral, Senem, Melek, Elif, Baslar, Zafer, Kaynar, Leylagul, Sevindik, Omur Gokmen
Format Journal Article
LanguageEnglish
Published Frontiers Media S.A 13.10.2023
Subjects
BCMA
bispecific Ab
CNS involvement
Elranatamab
Immunology
multiple myeloma
Online AccessGet full text

Cover

More Information
Summary:Central nervous system (CNS) involvement in multiple myeloma (MM) is a rare and challenging complication associated with poor prognosis and limited treatment options. Emerging T-cell directing therapies, such as bispecific antibodies (bsAbs) and chimeric antigen receptor T cells (CAR-T), have shown remarkable success in treating MM, but their efficacy in CNS involvement remains unclear. Elranatamab, a humanized bispecific antibody targeting B-cell maturation antigen (BCMA) and CD3-expressing T cells, has demonstrated promising results in relapsed refractory MM. However, its efficacy in treating CNS-MM has not been reported. We present a case of a 37-year-old male MM patient with CNS involvement who has been successfully treated with Elranatamab.
Bibliography:Reviewed by: Jaya Lakshmi Thangaraj, University of California, San Diego, United States; Yan-Hua Zheng, Fourth Military Medical University (Air Force Medical University), China
Edited by: Murali M. Yallapu, University of Tennessee Health Science Center (UTHSC), United States
ISSN:1664-3224
1664-3224
DOI:10.3389/fimmu.2023.1276295